VA HB2200 | 2023 | Regular Session

Status

Completed Legislative Action
Spectrum: Partisan Bill (Republican 1-0)
Status: Passed on March 26 2023 - 100% progression
Action: 2023-03-26 - Governor: Acts of Assembly Chapter text (CHAP0582)
Text: Latest bill text (Chaptered) [HTML]

Summary

License taxes; deductions; report. Directs the Secretary of Health and Human Resources to convene a work group to analyze and review current reimbursement and operational challenges for medical practices that administer anti-cancer drugs in an in-office setting. The bill requires the Secretary to report his recommendations to the Chairmen of the House Committee on Finance, the House Committee on Appropriations, the House Committee on Health, Welfare and Institutions, the Senate Committee on Finance and Appropriations, and the Senate Committee on Education and Health by November 15, 2023. License taxes; deductions; report. Directs the Secretary of Health and Human Resources to convene a work group to analyze and review current reimbursement and operational challenges for medical practices that administer anti-cancer drugs in an in-office setting. The bill requires the Secretary to report his recommendations to the Chairmen of the House Committee on Finance, the House Committee on Appropriations, the House Committee on Health, Welfare and Institutions, the Senate Committee on Finance and Appropriations, and the Senate Committee on Education and Health by November 15, 2023.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Anti-cancer drugs; analyzing current reimbursement, etc., for medical practices that administer.

Sponsors


Roll Calls

2023-02-22 - House - House: VOTE: Adoption (92-Y 0-N) (Y: 92 N: 0 NV: 0 Abs: 8) [PASS]
2023-02-21 - Senate - Senate: Passed Senate with substitute (40-Y 0-N) (Y: 40 N: 0 NV: 0 Abs: 0) [PASS]
2023-02-20 - Senate - Senate: Constitutional reading dispensed (40-Y 0-N) (Y: 40 N: 0 NV: 0 Abs: 0) [PASS]
2023-02-16 - Senate - Senate: Reported from Finance and Appropriations with substitute (16-Y 0-N) (Y: 16 N: 0 NV: 0 Abs: 0) [PASS]
2023-02-07 - House - House: VOTE: Passage (63-Y 35-N) (Y: 63 N: 35 NV: 0 Abs: 2) [PASS]
2023-02-01 - House - House: Reported from Finance (14-Y 8-N) (Y: 14 N: 8 NV: 0 Abs: 0) [PASS]
2023-01-30 - House - House: Subcommittee recommends reporting (6-Y 0-N) (Y: 6 N: 0 NV: 0 Abs: 2) [PASS]

History

DateChamberAction
2023-03-26 Governor: Acts of Assembly Chapter text (CHAP0582)
2023-03-26 Governor: Approved by Governor-Chapter 582 (effective 7/1/23)
2023-03-13 Governor: Governor's Action Deadline 11:59 p.m., March 27, 2023
2023-03-13HouseEnrolled Bill communicated to Governor on March 13, 2023
2023-03-08SenateSigned by President
2023-03-08HouseSigned by Speaker
2023-03-07HouseBill text as passed House and Senate (HB2200ER)
2023-03-07HouseEnrolled
2023-02-22HouseVOTE: Adoption (92-Y 0-N)
2023-02-22HouseSenate substitute agreed to by House 23107067D-S1 (92-Y 0-N)
2023-02-21SenatePassed Senate with substitute (40-Y 0-N)
2023-02-21SenateEngrossed by Senate - committee substitute HB2200S1
2023-02-21SenateCommittee substitute agreed to 23107067D-S1
2023-02-21SenateReading of substitute waived
2023-02-21SenateRead third time
2023-02-20SenateConstitutional reading dispensed (40-Y 0-N)
2023-02-16SenateCommittee substitute printed 23107067D-S1
2023-02-16SenateReported from Finance and Appropriations with substitute (16-Y 0-N)
2023-02-08SenateReferred to Committee on Finance and Appropriations
2023-02-08SenateConstitutional reading dispensed
2023-02-07HouseVOTE: Passage (63-Y 35-N)
2023-02-07HouseRead third time and passed House (63-Y 35-N)
2023-02-06HouseRead second time and engrossed
2023-02-03HouseRead first time
2023-02-01HouseReported from Finance (14-Y 8-N)
2023-01-30HouseSubcommittee recommends reporting (6-Y 0-N)
2023-01-26HouseAssigned Finance sub: Subcommittee #3
2023-01-11HouseReferred to Committee on Finance
2023-01-11HousePrefiled and ordered printed; offered 01/11/23 23103233D

Subjects


Code Citations

ChapterArticleSectionCitation TypeStatute Text
5813732(n/a)See Bill Text

Virginia State Sources

TypeSource
Summaryhttps://lis.virginia.gov/cgi-bin/legp604.exe?231+sum+HB2200
Texthttps://lis.virginia.gov/cgi-bin/legp604.exe?231+ful+HB2200+hil
Texthttps://lis.virginia.gov/cgi-bin/legp604.exe?231+ful+HB2200S1+hil
Texthttps://lis.virginia.gov/cgi-bin/legp604.exe?231+ful+HB2200ER+hil
Texthttps://lis.virginia.gov/cgi-bin/legp604.exe?231+ful+CHAP0582+hil
Amendmenthttps://committees.lis.virginia.gov/pdfs/drafts/23107067D.pdf
Supplementhttps://lis.virginia.gov/cgi-bin/legp604.exe?231+oth+HB2200F164+PDF
Supplementhttps://lis.virginia.gov/cgi-bin/legp604.exe?231+oth+HB2200F161+PDF
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?231+vot+H1003V0042+HB2200
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?231+vot+H10V0085+HB2200
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?231+vot+HV1577+HB2200
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?231+vot+S05V0450+HB2200
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?231+vot+SV0630HB2200+HB2200
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?231+vot+SV0679HB2200+HB2200
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?231+vot+HV2236+HB2200

Bill Comments

feedback